These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7085579)

  • 21. Medical mismanagement in public methadone programs.
    Blansfield HN
    Conn Med; 1994 Mar; 58(3):161-4. PubMed ID: 8039380
    [No Abstract]   [Full Text] [Related]  

  • 22. [Symptoms of hallucinogen and opiate use and withdrawal syndrome].
    Ladewig D
    Wien Med Wochenschr; 1981 Mar; 131(5):115-8. PubMed ID: 7233905
    [No Abstract]   [Full Text] [Related]  

  • 23. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome.
    Gallimberti L; Cibin M; Pagnin P; Sabbion R; Pani PP; Pirastu R; Ferrara SD; Gessa GL
    Neuropsychopharmacology; 1993 Aug; 9(1):77-81. PubMed ID: 8397726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clonidine in opiate withdrawal syndrome].
    Benos J
    Fortschr Med; 1985 Nov; 103(42):991-4. PubMed ID: 3908259
    [No Abstract]   [Full Text] [Related]  

  • 25. [Methadone, clonidine and levomepromazine in the treatment of opiate abstinence syndrome: double-blind clinical trial in heroin-addicted patients admitted to a general hospital for organic pathology].
    Vilalta J; Treserra J; García-Esteve L; García-Giralt M; Cirera E
    Med Clin (Barc); 1987 May; 88(17):674-6. PubMed ID: 3613695
    [No Abstract]   [Full Text] [Related]  

  • 26. PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users.
    Shi J; Zhao LY; Copersino ML; Fang YX; Chen Y; Tian J; Deng Y; Shuai Y; Jin J; Lu L
    Eur J Pharmacol; 2008 Jan; 579(1-3):160-6. PubMed ID: 17977528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users.
    Mitchell SG; Kelly SM; Brown BS; Reisinger HS; Peterson JA; Ruhf A; Agar MH; Schwartz RP
    J Psychoactive Drugs; 2009 Jun; 41(2):145-52. PubMed ID: 19705676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical use of clonidine in outpatient detoxification from opiates.
    Washton AM; Resnick RB
    Prog Clin Biol Res; 1981; 71():277-84. PubMed ID: 7330080
    [No Abstract]   [Full Text] [Related]  

  • 29. The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine.
    Koyuncuoğlu H; Saydam B
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):147-52. PubMed ID: 2187002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continued heroin use during methadone treatment: relationships between frequency of use and reasons reported for heroin use.
    Best D; Gossop M; Stewart D; Marsden J; Lehmann P; Strang J
    Drug Alcohol Depend; 1999 Feb; 53(3):191-5. PubMed ID: 10080044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Withdrawal from methadone maintenance. Impact of a tapering network support program.
    Sorensen JL; Trier M; Brummett S; Gold ML; Dumontet R
    J Subst Abuse Treat; 1992; 9(1):21-6. PubMed ID: 1593661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chlordiazepoxide vs. methadone in opiate withdrawal: a preliminary double blind trial.
    Drummond DC; Turkington D; Rahman MZ; Mullin PJ; Jackson P
    Drug Alcohol Depend; 1989 Jan; 23(1):63-71. PubMed ID: 2646089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects.
    De S; Jain R; Ray R; Dhawan A; Varghese ST
    Indian J Physiol Pharmacol; 2008; 52(1):53-63. PubMed ID: 18831352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The dysphoria of heroin addiction.
    Handelsman L; Aronson MJ; Ness R; Cochrane KJ; Kanof PD
    Am J Drug Alcohol Abuse; 1992; 18(3):275-87. PubMed ID: 1329491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low (40 mg) versus high (80 mg) dose methadone in a 180-day heroin detoxification program.
    Banys P; Tusel DJ; Sees KL; Reilly PM; Delucchi KL
    J Subst Abuse Treat; 1994; 11(3):225-32. PubMed ID: 8072050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic withdrawal psychosis in Tourette's disorder.
    Silva RR; Friedhoff AJ; Alpert M
    Biol Psychiatry; 1993 Sep; 34(5):341-2. PubMed ID: 8104510
    [No Abstract]   [Full Text] [Related]  

  • 37. Buprenorphine for acute heroin detoxification: diffusion of research into practice.
    Kovas AE; McFarland BH; McCarty DJ; Boverman JF; Thayer JA
    J Subst Abuse Treat; 2007 Mar; 32(2):199-206. PubMed ID: 17306728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrophysiological evidence of the motivational salience of drug cues in opiate addiction.
    Lubman DI; Allen NB; Peters LA; Deakin JF
    Psychol Med; 2007 Aug; 37(8):1203-9. PubMed ID: 17274853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opiate withdrawal with dextromethorphan.
    Bisaga A; Gianelli P; Popik P
    Am J Psychiatry; 1997 Apr; 154(4):584. PubMed ID: 9090360
    [No Abstract]   [Full Text] [Related]  

  • 40. Amantadine does not reduce cocaine use or craving in cocaine-dependent methadone maintenance patients.
    Handelsman L; Limpitlaw L; Williams D; Schmeidler J; Paris P; Stimmel B
    Drug Alcohol Depend; 1995 Oct; 39(3):173-80. PubMed ID: 8556965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.